Drug–drug interactions of new active substances: mibefradil example

@article{Krayenbhl1999DrugdrugIO,
  title={Drug–drug interactions of new active substances: mibefradil example},
  author={J. C. Krayenb{\"u}hl and S. Vozeh and Mitsuko Kondo-Oestreicher and Pierre Dayer},
  journal={European Journal of Clinical Pharmacology},
  year={1999},
  volume={55},
  pages={559-565}
}
Introduction: Mibefradil was approved as a novel calcium antagonist in Switzerland in 1996. Following its launch as an antihypertensive and anti-anginal agent, there were reports about serious pharmacokinetic and pharmacodynamic interactions occurring with other drugs frequently administered to patients with cardiovascular diseases. Despite appropriate modifications of the prescribing information, such interactions continued to occur. The drug was finally withdrawn after a study in patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Induktion von Bradykardie durch Mibefradil bei antihypertensiver Kombinationstherapie

  • J Wagner, E Ritz
  • Deutsche Med Wochenschr
  • 1998
1 Excerpt

Interaction entre tacrolimus et mibe fradil Schweiz (abstract)

  • A Menafoglio, S KraÈ henbuÈ hl, +4 authors A Gallino
  • Med Wochenschr 128[suppl
  • 1998
1 Excerpt

Similar Papers

Loading similar papers…